TargetMol

RP5063 Hydrochloride

Product Code:
 
TAR-T24736
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T24736-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T24736-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T24736-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
RP5063 Hydrochloride is a modulator of multimodal serotonin receptors.
CAS:
1708960-04-6
Formula:
C22H26Cl3N3O3
Molecular Weight:
486.82
Purity:
0.98
SMILES:
Cl.Clc1cccc(N2CCN(CCCCOc3ccc4OCC(=O)Nc4c3)CC2)c1Cl

References

1. Bhat L, Hawkinson J, Cantillon M, Reddy DG, Bhat SR, Laurent CE, Bouchard A, Biernat M, Salvail D. Evaluation of the effects of RP5063, a novel, multimodal, serotonin receptor modulator, as single-agent therapy and co-administrated with sildenafil, bosentan, and treprostinil in a monocrotaline-induced pulmonary arterial hypertension rat model. Eur J Pharmacol. 2018 Feb 14. pii: S0014-2999(18)30096-7. doi: 10.1016/j.ejphar.2018.02.017. [Epub ahead of print] PubMed PMID: 29453947. 2. Cantillon M, Bhat L. Response to concerns over Cantillon et al. dopamine serotonin stabilizer RP5063 clinical trial's design, analyses and findings (SCHRES-D-17-00455) by Ahmed S Aboraya, MD, DrPh. Schizophr Res. 2018 Jan 21. pii: S0920-9964(17)30569-8. doi: 10.1016/j.schres.2017.09.010. [Epub ahead of print] PubMed PMID: 29395606. 3. Cantillon M, Ings R, Bhat L. Pharmacokinetics of RP5063 Following Single Doses to Normal Healthy Volunteers and Multiple Doses Over 10 Days to Stable Schizophrenic Patients. Clin Transl Sci. 2017 Nov 8. doi: 10.1111/cts.12518. [Epub ahead of print] PubMed PMID: 29119704. 4. Aboraya A. Concerns about the design, analyses, and findings of the trial of dopamine serotonin stabilizer RP5063 by Cantillon and colleagues. Schizophr Res. 2017 Aug 25. pii: S0920-9964(17)30508-X. doi: 10.1016/j.schres.2017.08.034. [Epub ahead of print] PubMed PMID: 28847613.